-
1
-
-
84897381734
-
GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012
-
(3 April 2015, date last accessed)
-
WHO. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012; http://globocan.iarc.fr/Pages/fact_sheets_population. aspx (3 April 2015, date last accessed).
-
(2012)
-
-
-
2
-
-
33847366564
-
Prognostic factors for uterine cancer in reproductive-aged women
-
Lee NK, Cheung MK, Shin JY et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol 2007; 109: 655-662.
-
(2007)
Obstet Gynecol
, vol.109
, pp. 655-662
-
-
Lee, N.K.1
Cheung, M.K.2
Shin, J.Y.3
-
3
-
-
84953302182
-
Endometrial cancer treatment Physician Data Query (PDQ)
-
(1 April 2015, date last accessed)
-
National Cancer Institute. Endometrial cancer treatment Physician Data Query (PDQ). 2015; http://www.cancer.gov/cancertopics/pdq/treatment/endometrial/ healthprofessional (1 April 2015, date last accessed).
-
(2015)
-
-
-
4
-
-
22544448651
-
ACOG practice bulletin, clinical management guidelines for obstetriciangynecologists, number 65, August 2005: management of endometrial cancer
-
ACOG. ACOG practice bulletin, clinical management guidelines for obstetriciangynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005; 106: 413-425.
-
(2005)
Obstet Gynecol
, vol.106
, pp. 413-425
-
-
-
5
-
-
84877254190
-
Integrated genomic characterization of endometrial carcinoma
-
Kandoth C, Schultz N, Cherniack AD et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
-
(2013)
Nature
, vol.497
, pp. 67-73
-
-
Kandoth, C.1
Schultz, N.2
Cherniack, A.D.3
-
6
-
-
33746312861
-
Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis
-
Reid-Nicholson M, Iyengar P, Hummer AJ et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006; 19: 1091-1100.
-
(2006)
Mod Pathol
, vol.19
, pp. 1091-1100
-
-
Reid-Nicholson, M.1
Iyengar, P.2
Hummer, A.J.3
-
7
-
-
29744432124
-
Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma
-
Broaddus RR, Lynch HT, Chen LM et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006; 106: 87-94.
-
(2006)
Cancer
, vol.106
, pp. 87-94
-
-
Broaddus, R.R.1
Lynch, H.T.2
Chen, L.M.3
-
8
-
-
84885354186
-
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
Colombo N, Preti E, Landoni F et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi33-vi38.
-
(2013)
Ann Oncol
, vol.24
, pp. vi33-vi38
-
-
Colombo, N.1
Preti, E.2
Landoni, F.3
-
9
-
-
0035879607
-
Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
-
Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.
-
(2001)
Clin Infect Dis
, vol.33
, pp. 139-144
-
-
Dykewicz, C.A.1
-
10
-
-
84887310345
-
Continuous Update Project Report
-
Food, Nutrition, Physical Activity, and the Prevention of Endometrial Cancer, (2 April 2015, date last accessed)
-
World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report. Food, Nutrition, Physical Activity, and the Prevention of Endometrial Cancer. 2013; http://www.dietandcancerreport.org (2 April 2015, date last accessed).
-
(2013)
-
-
-
11
-
-
84895540960
-
Endometrial carcinoma in women aged 40 years and younger
-
Garg K, Soslow RA. Endometrial carcinoma in women aged 40 years and younger. Arch Pathol Lab Med 2014; 138: 335-342.
-
(2014)
Arch Pathol Lab Med
, vol.138
, pp. 335-342
-
-
Garg, K.1
Soslow, R.A.2
-
12
-
-
84876787194
-
Metabolic syndrome and endometrial cancer: a meta-analysis
-
Esposito K, Chiodini P, Capuano A et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 2014; 45: 28-36.
-
(2014)
Endocrine
, vol.45
, pp. 28-36
-
-
Esposito, K.1
Chiodini, P.2
Capuano, A.3
-
13
-
-
84897847172
-
Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis
-
Zhang Y, Liu H, Yang S et al. Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. Int J Biol Markers 2014; 29: e21-e29.
-
(2014)
Int J Biol Markers
, vol.29
, pp. e21-e29
-
-
Zhang, Y.1
Liu, H.2
Yang, S.3
-
14
-
-
79953295548
-
Metabolic syndrome and endometrial cancer risk
-
Rosato V, Zucchetto A, Bosetti C et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol 2011; 22: 884-889.
-
(2011)
Ann Oncol
, vol.22
, pp. 884-889
-
-
Rosato, V.1
Zucchetto, A.2
Bosetti, C.3
-
15
-
-
84909997906
-
Association between diabetes, diabetes treatment and risk of developing endometrial cancer
-
Luo J, Beresford S, Chen C et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer 2014; 111: 1432-1439.
-
(2014)
Br J Cancer
, vol.111
, pp. 1432-1439
-
-
Luo, J.1
Beresford, S.2
Chen, C.3
-
16
-
-
84905082203
-
Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and metaanalysis
-
Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and metaanalysis. Hum Reprod Update 2014; 20: 748-758.
-
(2014)
Hum Reprod Update
, vol.20
, pp. 748-758
-
-
Barry, J.A.1
Azizia, M.M.2
Hardiman, P.J.3
-
17
-
-
67349141286
-
Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship
-
Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009; 114: 121-127.
-
(2009)
Gynecol Oncol
, vol.114
, pp. 121-127
-
-
Fader, A.N.1
Arriba, L.N.2
Frasure, H.E.3
von Gruenigen, V.E.4
-
18
-
-
84900387268
-
Reproductive factors and the risk of endometrial cancer
-
Ali AT. Reproductive factors and the risk of endometrial cancer. Int J Gynecol Cancer 2014; 24: 384-393.
-
(2014)
Int J Gynecol Cancer
, vol.24
, pp. 384-393
-
-
Ali, A.T.1
-
19
-
-
84953207493
-
Sex cord-stromal tumors of the ovary
-
Ankara and Istanbul: Günes Publishing
-
Peiretti M, Colombo N. Sex cord-stromal tumors of the ovary. In Textbook of Gynaecological Oncology. Ankara and Istanbul: Günes Publishing, 2012; 453-456.
-
(2012)
Textbook of Gynaecological Oncology
, pp. 453-456
-
-
Peiretti, M.1
Colombo, N.2
-
20
-
-
0026453702
-
Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study
-
Brinton LA, Berman ML, Mortel R et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 1992; 167: 1317-1325.
-
(1992)
Am J Obstet Gynecol
, vol.167
, pp. 1317-1325
-
-
Brinton, L.A.1
Berman, M.L.2
Mortel, R.3
-
21
-
-
68649121618
-
Hormone-related factors and gynecological conditions in relation to endometrial cancer risk
-
Zucchetto A, Serraino D, Polesel J et al. Hormone-related factors and gynecological conditions in relation to endometrial cancer risk. Eur J Cancer Prev 2009; 18: 316-321.
-
(2009)
Eur J Cancer Prev
, vol.18
, pp. 316-321
-
-
Zucchetto, A.1
Serraino, D.2
Polesel, J.3
-
22
-
-
0032537990
-
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
-
Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 1371-1388
-
-
Fisher, B.1
Costantino, J.P.2
Wickerham, D.L.3
-
23
-
-
84925229366
-
Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions
-
Lancaster JM, Powell CB, Chen LM, Richardson DL. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2015; 136: 3-7.
-
(2015)
Gynecol Oncol
, vol.136
, pp. 3-7
-
-
Lancaster, J.M.1
Powell, C.B.2
Chen, L.M.3
Richardson, D.L.4
-
24
-
-
58849114609
-
Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening
-
Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009; 59: 27-41.
-
(2009)
CA Cancer J Clin
, vol.59
, pp. 27-41
-
-
Smith, R.A.1
Cokkinides, V.2
Brawley, O.W.3
-
25
-
-
78650687714
-
Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort
-
Jacobs I, Gentry-Maharaj A, Burnell M et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol 2011; 12: 38-48.
-
(2011)
Lancet Oncol
, vol.12
, pp. 38-48
-
-
Jacobs, I.1
Gentry-Maharaj, A.2
Burnell, M.3
-
26
-
-
84953302182
-
Endometrial Cancer Screening Physician Data Query (PDQ)
-
2 April 2015, date last accessed)
-
National Cancer Institute. Endometrial Cancer Screening Physician Data Query (PDQ). 2015; www.cancer.gov/cancertopics/pdq/screening/endometrial/ HealthProfessional/ (2 April 2015, date last accessed).
-
(2015)
-
-
-
27
-
-
84901391552
-
Committee Opinion No. 601: tamoxifen and uterine cancer
-
ACOG. Committee Opinion No. 601: tamoxifen and uterine cancer. Obstet Gynecol 2014; 123: 1394-1397.
-
(2014)
Obstet Gynecol
, vol.123
, pp. 1394-1397
-
-
-
28
-
-
84912075615
-
Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis
-
Fu Y, Zhuang Z. Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis. Int J Clin Exp Pathol 2014; 7: 6419-6429.
-
(2014)
Int J Clin Exp Pathol
, vol.7
, pp. 6419-6429
-
-
Fu, Y.1
Zhuang, Z.2
-
29
-
-
84877594960
-
Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS)
-
Manchanda R, Saridogan E, Abdelraheim A et al. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). Arch Gynecol Obstet 2012; 286: 1555-1562.
-
(2012)
Arch Gynecol Obstet
, vol.286
, pp. 1555-1562
-
-
Manchanda, R.1
Saridogan, E.2
Abdelraheim, A.3
-
30
-
-
84876900933
-
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts
-
Vasen HF, Blanco I, Aktan-Collan K et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013; 62: 812-823.
-
(2013)
Gut
, vol.62
, pp. 812-823
-
-
Vasen, H.F.1
Blanco, I.2
Aktan-Collan, K.3
-
31
-
-
0034755101
-
Endometrial cancer in women 40 years old or younger
-
Duska LR, Garrett A, Rueda BR et al. Endometrial cancer in women 40 years old or younger. Gynecol Oncol 2001; 83: 388-393.
-
(2001)
Gynecol Oncol
, vol.83
, pp. 388-393
-
-
Duska, L.R.1
Garrett, A.2
Rueda, B.R.3
-
33
-
-
84940930055
-
European Society of Gynecological Oncology Task Force for Fertility Preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients
-
Rodolakis A, Biliatis I, Morice P et al. European Society of Gynecological Oncology Task Force for Fertility Preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer 2015; 25: 1258-1265.
-
(2015)
Int J Gynecol Cancer
, vol.25
, pp. 1258-1265
-
-
Rodolakis, A.1
Biliatis, I.2
Morice, P.3
-
34
-
-
62549137810
-
Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma
-
Leitao MM, Jr, Kehoe S, Barakat RR et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2009; 113: 105-108.
-
(2009)
Gynecol Oncol
, vol.113
, pp. 105-108
-
-
Leitao, M.M.1
Kehoe, S.2
Barakat, R.R.3
-
35
-
-
34447579172
-
Multicenter phase II study of fertilitysparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women
-
Ushijima K, Yahata H, Yoshikawa H et al. Multicenter phase II study of fertilitysparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007; 25: 2798-2803.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2798-2803
-
-
Ushijima, K.1
Yahata, H.2
Yoshikawa, H.3
-
36
-
-
0032860063
-
Radiologic staging in patients with endometrial cancer: a meta-analysis
-
Kinkel K, Kaji Y, Yu KK et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 1999; 212: 711-718.
-
(1999)
Radiology
, vol.212
, pp. 711-718
-
-
Kinkel, K.1
Kaji, Y.2
Yu, K.K.3
-
37
-
-
79952024674
-
Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women
-
Minig L, Franchi D, Boveri S et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol 2011; 22: 643-649.
-
(2011)
Ann Oncol
, vol.22
, pp. 643-649
-
-
Minig, L.1
Franchi, D.2
Boveri, S.3
-
38
-
-
84882455434
-
Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer
-
Kim MK, Seong SJ, Song T et al. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer. Gynecol Oncol 2013; 130: 470-473.
-
(2013)
Gynecol Oncol
, vol.130
, pp. 470-473
-
-
Kim, M.K.1
Seong, S.J.2
Song, T.3
-
39
-
-
84866846627
-
Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis
-
Gallos ID, Yap J, Rajkhowa M et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207: 266.e1-266.e12.
-
(2012)
Am J Obstet Gynecol
, vol.207
, pp. 266.e1-266.e12
-
-
Gallos, I.D.1
Yap, J.2
Rajkhowa, M.3
-
40
-
-
84873704819
-
Long-term oncologic outcomes after fertilitysparing management using oral progestin for young women with endometrial cancer (KGOG 2002)
-
Park JY, Kim DY, Kim JH et al. Long-term oncologic outcomes after fertilitysparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer 2013; 49: 868-874.
-
(2013)
Eur J Cancer
, vol.49
, pp. 868-874
-
-
Park, J.Y.1
Kim, D.Y.2
Kim, J.H.3
-
42
-
-
79960681651
-
Fertility-sparing therapy in young women with endometrial cancer: 2010 update
-
Erkanli S, Ayhan A. Fertility-sparing therapy in young women with endometrial cancer: 2010 update. Int J Gynecol Cancer 2010; 20: 1170-1187.
-
(2010)
Int J Gynecol Cancer
, vol.20
, pp. 1170-1187
-
-
Erkanli, S.1
Ayhan, A.2
-
43
-
-
34447335590
-
Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer
-
Yamazawa K, Hirai M, Fujito A et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 2007; 22: 1953-1958.
-
(2007)
Hum Reprod
, vol.22
, pp. 1953-1958
-
-
Yamazawa, K.1
Hirai, M.2
Fujito, A.3
-
44
-
-
84894493540
-
Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis
-
Koskas M, Uzan J, Luton D et al. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril 2014; 101: 785-794.
-
(2014)
Fertil Steril
, vol.101
, pp. 785-794
-
-
Koskas, M.1
Uzan, J.2
Luton, D.3
-
45
-
-
40349098656
-
Application of immunohistochemistry to gynecologic pathology
-
Mittal K, Soslow R, McCluggage WG. Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med 2008; 132: 402-423.
-
(2008)
Arch Pathol Lab Med
, vol.132
, pp. 402-423
-
-
Mittal, K.1
Soslow, R.2
McCluggage, W.G.3
-
46
-
-
0035220843
-
Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia
-
Sun H, Enomoto T, Fujita M et al. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol 2001; 115: 32-38.
-
(2001)
Am J Clin Pathol
, vol.115
, pp. 32-38
-
-
Sun, H.1
Enomoto, T.2
Fujita, M.3
-
47
-
-
0037378452
-
Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia
-
Orbo A, Nilsen MN, Arnes MS et al. Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia. Int J Gynecol Pathol 2003; 22: 141-148.
-
(2003)
Int J Gynecol Pathol
, vol.22
, pp. 141-148
-
-
Orbo, A.1
Nilsen, M.N.2
Arnes, M.S.3
-
48
-
-
1542724875
-
Enhanced detection of atypical hyperplasia in endometrial polyps by PTEN expression
-
Hecht JL, Pinkus JL, Pinkus GS. Enhanced detection of atypical hyperplasia in endometrial polyps by PTEN expression. Appl Immunohistochem Mol Morphol 2004; 12: 36-39.
-
(2004)
Appl Immunohistochem Mol Morphol
, vol.12
, pp. 36-39
-
-
Hecht, J.L.1
Pinkus, J.L.2
Pinkus, G.S.3
-
49
-
-
77955360642
-
Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer
-
Monte NM, Webster KA, Neuberg D et al. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Res 2010; 70: 6225-6232.
-
(2010)
Cancer Res
, vol.70
, pp. 6225-6232
-
-
Monte, N.M.1
Webster, K.A.2
Neuberg, D.3
-
50
-
-
84857155080
-
PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia
-
Allison KH, Upson K, Reed SD et al. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia. Int J Gynecol Pathol 2012; 31: 151-159.
-
(2012)
Int J Gynecol Pathol
, vol.31
, pp. 151-159
-
-
Allison, K.H.1
Upson, K.2
Reed, S.D.3
-
51
-
-
84868142801
-
Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia
-
Quick CM, Laury AR, Monte NM, Mutter GL. Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia. Am J Clin Pathol 2012; 138: 678-684.
-
(2012)
Am J Clin Pathol
, vol.138
, pp. 678-684
-
-
Quick, C.M.1
Laury, A.R.2
Monte, N.M.3
Mutter, G.L.4
-
52
-
-
0031012928
-
p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis
-
Tashiro H, Isacson C, Levine R et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997; 150: 177-185.
-
(1997)
Am J Pathol
, vol.150
, pp. 177-185
-
-
Tashiro, H.1
Isacson, C.2
Levine, R.3
-
53
-
-
0031769404
-
p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma
-
Zheng W, Khurana R, Farahmand S et al. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol 1998; 22: 1463-1473.
-
(1998)
Am J Surg Pathol
, vol.22
, pp. 1463-1473
-
-
Zheng, W.1
Khurana, R.2
Farahmand, S.3
-
54
-
-
42249113463
-
Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma
-
Jia L, Liu Y, Yi X et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res 2008; 14: 2263-2269.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 2263-2269
-
-
Jia, L.1
Liu, Y.2
Yi, X.3
-
55
-
-
0034651530
-
The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways
-
Lax SF, Kendall B, Tashiro H et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000; 88: 814-824.
-
(2000)
Cancer
, vol.88
, pp. 814-824
-
-
Lax, S.F.1
Kendall, B.2
Tashiro, H.3
-
56
-
-
0036134090
-
Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study
-
Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol 2002; 21: 4-10.
-
(2002)
Int J Gynecol Pathol
, vol.21
, pp. 4-10
-
-
Castrillon, D.H.1
Lee, K.R.2
Nucci, M.R.3
-
57
-
-
84856686339
-
P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin
-
Saad RS, Mashhour M, Noftech-Mozes S et al. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin. Int J Gynecol Pathol 2012; 31: 57-65.
-
(2012)
Int J Gynecol Pathol
, vol.31
, pp. 57-65
-
-
Saad, R.S.1
Mashhour, M.2
Noftech-Mozes, S.3
-
58
-
-
84857467696
-
Diagnostic implications of p16 expression in serous papillary endometrial cancer
-
Netzer IM, Kerner H, Litwin L et al. Diagnostic implications of p16 expression in serous papillary endometrial cancer. Int J Gynecol Cancer 2011; 21: 1441-1445.
-
(2011)
Int J Gynecol Cancer
, vol.21
, pp. 1441-1445
-
-
Netzer, I.M.1
Kerner, H.2
Litwin, L.3
-
59
-
-
84883463832
-
Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin
-
Bagby C, Ronnett BM, Yemelyanova A et al. Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin. Int J Gynecol Pathol 2013; 32: 433-443.
-
(2013)
Int J Gynecol Pathol
, vol.32
, pp. 433-443
-
-
Bagby, C.1
Ronnett, B.M.2
Yemelyanova, A.3
-
60
-
-
0141680966
-
Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum
-
Hashi A, Yuminamochi T, Murata S et al. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol 2003; 22: 374-377.
-
(2003)
Int J Gynecol Pathol
, vol.22
, pp. 374-377
-
-
Hashi, A.1
Yuminamochi, T.2
Murata, S.3
-
61
-
-
59149101397
-
A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary
-
Köbel M, Kalloger SE, Carrick J et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009; 33: 14-21.
-
(2009)
Am J Surg Pathol
, vol.33
, pp. 14-21
-
-
Köbel, M.1
Kalloger, S.E.2
Carrick, J.3
-
62
-
-
1542270080
-
WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma
-
Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004; 44: 109-115.
-
(2004)
Histopathology
, vol.44
, pp. 109-115
-
-
Al-Hussaini, M.1
Stockman, A.2
Foster, H.3
McCluggage, W.G.4
-
63
-
-
1642284785
-
Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium
-
Egan JA, Ionescu MC, Eapen E et al. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 2004; 23: 119-122.
-
(2004)
Int J Gynecol Pathol
, vol.23
, pp. 119-122
-
-
Egan, J.A.1
Ionescu, M.C.2
Eapen, E.3
-
64
-
-
84926383409
-
Transvaginal ultrasound assessment of myometrial and cervical stromal invasion in women with endometrial cancer: interobserver reproducibility among ultrasound experts and gynecologists
-
Eriksson LS, Lindqvist PG, Flöter Rådestad A et al. Transvaginal ultrasound assessment of myometrial and cervical stromal invasion in women with endometrial cancer: interobserver reproducibility among ultrasound experts and gynecologists. Ultrasound Obstet Gynecol 2015; 45: 476-482.
-
(2015)
Ultrasound Obstet Gynecol
, vol.45
, pp. 476-482
-
-
Eriksson, L.S.1
Lindqvist, P.G.2
Flöter Rådestad, A.3
-
66
-
-
0842304361
-
Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma
-
Scholten AN, Smit VT, Beerman H et al. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 2004; 100: 764-772.
-
(2004)
Cancer
, vol.100
, pp. 764-772
-
-
Scholten, A.N.1
Smit, V.T.2
Beerman, H.3
-
67
-
-
84893786639
-
Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer
-
Helpman L, Kupets R, Covens A et al. Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer. Br J Cancer 2014; 110: 609-615.
-
(2014)
Br J Cancer
, vol.110
, pp. 609-615
-
-
Helpman, L.1
Kupets, R.2
Covens, A.3
-
68
-
-
84901648475
-
Intra-operative frozen section results reliably predict final pathology in endometrial cancer
-
Stephan JM, Hansen J, Samuelson M et al. Intra-operative frozen section results reliably predict final pathology in endometrial cancer. Gynecol Oncol 2014; 133: 499-505.
-
(2014)
Gynecol Oncol
, vol.133
, pp. 499-505
-
-
Stephan, J.M.1
Hansen, J.2
Samuelson, M.3
-
69
-
-
84886892919
-
HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET)
-
Antonsen SL, Høgdall E, Christensen IJ et al. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand 2013; 92: 1313-1322.
-
(2013)
Acta Obstet Gynecol Scand
, vol.92
, pp. 1313-1322
-
-
Antonsen, S.L.1
Høgdall, E.2
Christensen, I.J.3
-
70
-
-
84866728682
-
Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma
-
Yildiz A, Yetimalar H, Kasap B et al. Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 2012; 164: 191-195.
-
(2012)
Eur J Obstet Gynecol Reprod Biol
, vol.164
, pp. 191-195
-
-
Yildiz, A.1
Yetimalar, H.2
Kasap, B.3
-
71
-
-
84862886235
-
HE4 is an independent prognostic marker in endometrial cancer patients
-
Mutz-Dehbalaie I, Egle D, Fessler S et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol 2012; 126: 186-191.
-
(2012)
Gynecol Oncol
, vol.126
, pp. 186-191
-
-
Mutz-Dehbalaie, I.1
Egle, D.2
Fessler, S.3
-
72
-
-
84883459439
-
Safety of ovarian preservation in young patients with early-stage endometrial cancer: a retrospective study and meta-analysis
-
Sun C, Chen G, Yang Z et al. Safety of ovarian preservation in young patients with early-stage endometrial cancer: a retrospective study and meta-analysis. Fertil Steril 2013; 100: 782-787.
-
(2013)
Fertil Steril
, vol.100
, pp. 782-787
-
-
Sun, C.1
Chen, G.2
Yang, Z.3
-
73
-
-
73949107889
-
Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2
-
Walker JL, Piedmonte MR, Spirtos NM et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009; 27: 5331-5336.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5331-5336
-
-
Walker, J.L.1
Piedmonte, M.R.2
Spirtos, N.M.3
-
74
-
-
77955268275
-
Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial
-
Mourits MJ, Bijen CB, Arts HJ et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol 2010; 11: 763-771.
-
(2010)
Lancet Oncol
, vol.11
, pp. 763-771
-
-
Mourits, M.J.1
Bijen, C.B.2
Arts, H.J.3
-
75
-
-
84862978252
-
Safety of laparoscopy vs laparotomy in the surgical staging of endometrial cancer: a systematic review and metaanalysis of randomized controlled trials
-
Zullo F, Falbo A, Palomba S. Safety of laparoscopy vs laparotomy in the surgical staging of endometrial cancer: a systematic review and metaanalysis of randomized controlled trials. Am J Obstet Gynecol 2012; 207: 94-100.
-
(2012)
Am J Obstet Gynecol
, vol.207
, pp. 94-100
-
-
Zullo, F.1
Falbo, A.2
Palomba, S.3
-
76
-
-
84894027918
-
A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma
-
Pakish J, Soliman PT, Frumovitz M et al. A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. Gynecol Oncol 2014; 132: 366-371.
-
(2014)
Gynecol Oncol
, vol.132
, pp. 366-371
-
-
Pakish, J.1
Soliman, P.T.2
Frumovitz, M.3
-
77
-
-
15544373622
-
Analysis of morbidity in patients with endometrial cancer: is there a commitment to offer laparoscopy?
-
Tozzi R, Malur S, Koehler C, Schneider A. Analysis of morbidity in patients with endometrial cancer: is there a commitment to offer laparoscopy? Gynecol Oncol 2005; 97: 4-9.
-
(2005)
Gynecol Oncol
, vol.97
, pp. 4-9
-
-
Tozzi, R.1
Malur, S.2
Koehler, C.3
Schneider, A.4
-
78
-
-
77952267504
-
Surgical and survival outcomes in older women with endometrial cancer treated by laparoscopy
-
Siesto G, Uccella S, Ghezzi F et al. Surgical and survival outcomes in older women with endometrial cancer treated by laparoscopy. Menopause 2010; 17: 539-544.
-
(2010)
Menopause
, vol.17
, pp. 539-544
-
-
Siesto, G.1
Uccella, S.2
Ghezzi, F.3
-
79
-
-
58149510327
-
Laparoscopic treatment for endometrial cancer: a meta-analysis of randomized controlled trials (RCTs)
-
Palomba S, Falbo A, Mocciaro R et al. Laparoscopic treatment for endometrial cancer: a meta-analysis of randomized controlled trials (RCTs). Gynecol Oncol 2009; 112: 415-421.
-
(2009)
Gynecol Oncol
, vol.112
, pp. 415-421
-
-
Palomba, S.1
Falbo, A.2
Mocciaro, R.3
-
80
-
-
67349124841
-
Updating of a recent meta-analysis of randomized controlled trials to assess the safety and the efficacy of the laparoscopic surgery for treating early stage endometrial cancer
-
Palomba S, Falbo A, Russo T, Zullo F. Updating of a recent meta-analysis of randomized controlled trials to assess the safety and the efficacy of the laparoscopic surgery for treating early stage endometrial cancer. Gynecol Oncol 2009; 114: 135-136.
-
(2009)
Gynecol Oncol
, vol.114
, pp. 135-136
-
-
Palomba, S.1
Falbo, A.2
Russo, T.3
Zullo, F.4
-
81
-
-
84863393302
-
Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study
-
Walker JL, Piedmonte MR, Spirtos NM et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 2012; 30: 695-700.
-
(2012)
J Clin Oncol
, vol.30
, pp. 695-700
-
-
Walker, J.L.1
Piedmonte, M.R.2
Spirtos, N.M.3
-
82
-
-
84862862331
-
Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers
-
Fader AN, Seamon LG, Escobar PF et al. Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers. Gynecol Oncol 2012; 126: 180-185.
-
(2012)
Gynecol Oncol
, vol.126
, pp. 180-185
-
-
Fader, A.N.1
Seamon, L.G.2
Escobar, P.F.3
-
83
-
-
84905581356
-
Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer
-
Han KH, Park NH, Kim HS et al. Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer. Gynecol Oncol 2014; 134: 293-296.
-
(2014)
Gynecol Oncol
, vol.134
, pp. 293-296
-
-
Han, K.H.1
Park, N.H.2
Kim, H.S.3
-
84
-
-
84871922686
-
Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer
-
Garg G, Gao F, Wright JD et al. Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Gynecol Oncol 2013; 128: 77-82.
-
(2013)
Gynecol Oncol
, vol.128
, pp. 77-82
-
-
Garg, G.1
Gao, F.2
Wright, J.D.3
-
85
-
-
33745029084
-
Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology
-
Lutman CV, Havrilesky LJ, Cragun JM et al. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol 2006; 102: 92-97.
-
(2006)
Gynecol Oncol
, vol.102
, pp. 92-97
-
-
Lutman, C.V.1
Havrilesky, L.J.2
Cragun, J.M.3
-
86
-
-
41349095877
-
Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?
-
discussion 457.e5-457.e6
-
Abu-Rustum NR, Iasonos A, Zhou Q et al. Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? Am J Obstet Gynecol 2008; 198: 457.e1-457.e5; discussion 457.e5-457.e6.
-
(2008)
Am J Obstet Gynecol
, vol.198
, pp. 457.e1-457.e5
-
-
Abu-Rustum, N.R.1
Iasonos, A.2
Zhou, Q.3
-
87
-
-
20544477431
-
Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer
-
Cragun JM, Havrilesky LJ, Calingaert B et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005; 23: 3668-3675.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3668-3675
-
-
Cragun, J.M.1
Havrilesky, L.J.2
Calingaert, B.3
-
88
-
-
0028942190
-
Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling
-
Kilgore LC, Partridge EE, Alvarez RD et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995; 56: 29-33.
-
(1995)
Gynecol Oncol
, vol.56
, pp. 29-33
-
-
Kilgore, L.C.1
Partridge, E.E.2
Alvarez, R.D.3
-
89
-
-
0023232969
-
Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study
-
Creasman WT, Morrow CP, Bundy BN et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987; 60(8 Suppl): 2035-2041.
-
(1987)
Cancer
, vol.60
, Issue.8
, pp. 2035-2041
-
-
Creasman, W.T.1
Morrow, C.P.2
Bundy, B.N.3
-
90
-
-
70349745230
-
The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes
-
Abu-Rustum NR, Gomez JD, Alektiar KM et al. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol 2009; 115: 236-238.
-
(2009)
Gynecol Oncol
, vol.115
, pp. 236-238
-
-
Abu-Rustum, N.R.1
Gomez, J.D.2
Alektiar, K.M.3
-
91
-
-
56449101720
-
Extra-peritoneal laparoscopic para-aortic lymphadenectomy-a prospective cohort study of 293 patients with endometrial cancer
-
Dowdy SC, Aletti G, Cliby WA et al. Extra-peritoneal laparoscopic para-aortic lymphadenectomy-a prospective cohort study of 293 patients with endometrial cancer. Gynecol Oncol 2008; 111: 418-424.
-
(2008)
Gynecol Oncol
, vol.111
, pp. 418-424
-
-
Dowdy, S.C.1
Aletti, G.2
Cliby, W.A.3
-
92
-
-
40949141349
-
Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging
-
Mariani A, Dowdy SC, Cliby WA et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008; 109: 11-18.
-
(2008)
Gynecol Oncol
, vol.109
, pp. 11-18
-
-
Mariani, A.1
Dowdy, S.C.2
Cliby, W.A.3
-
93
-
-
79955483215
-
Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO)
-
Ballester M, Dubernard G, Lécuru F et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol 2011; 12: 469-476.
-
(2011)
Lancet Oncol
, vol.12
, pp. 469-476
-
-
Ballester, M.1
Dubernard, G.2
Lécuru, F.3
-
94
-
-
84895828864
-
Sentinel lymph node mapping for endometrial cancer: a modern approach to surgical staging
-
Abu-Rustum NR. Sentinel lymph node mapping for endometrial cancer: a modern approach to surgical staging. J Natl Compr Canc Netw 2014; 12: 288-297.
-
(2014)
J Natl Compr Canc Netw
, vol.12
, pp. 288-297
-
-
Abu-Rustum, N.R.1
-
95
-
-
57349198710
-
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial
-
Benedetti Panici P, Basile S, Maneschi F et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008; 100: 1707-1716.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 1707-1716
-
-
Benedetti Panici, P.1
Basile, S.2
Maneschi, F.3
-
96
-
-
58149191223
-
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study
-
Kitchener H, Swart AM, Qian Q et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009; 373: 125-136.
-
(2009)
Lancet
, vol.373
, pp. 125-136
-
-
Kitchener, H.1
Swart, A.M.2
Qian, Q.3
-
97
-
-
84862771599
-
The role of lymphadenectomy in endometrial cancer: was the ASTEC trial doomed by design and are we destined to repeat that mistake?
-
Naumann RW. The role of lymphadenectomy in endometrial cancer: was the ASTEC trial doomed by design and are we destined to repeat that mistake? Gynecol Oncol 2012; 126: 5-11.
-
(2012)
Gynecol Oncol
, vol.126
, pp. 5-11
-
-
Naumann, R.W.1
-
98
-
-
40549135709
-
Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis
-
Smith DC, Macdonald OK, Lee CM, Gaffney DK. Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis. Int J Gynecol Cancer 2008; 18: 255-261.
-
(2008)
Int J Gynecol Cancer
, vol.18
, pp. 255-261
-
-
Smith, D.C.1
Macdonald, O.K.2
Lee, C.M.3
Gaffney, D.K.4
-
99
-
-
0032422316
-
Lymph node sampling and survival in endometrial cancer
-
Trimble EL, Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 1998; 71: 340-343.
-
(1998)
Gynecol Oncol
, vol.71
, pp. 340-343
-
-
Trimble, E.L.1
Kosary, C.2
Park, R.C.3
-
100
-
-
77950188128
-
Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis
-
Todo Y, Kato H, Kaneuchi M et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010; 375: 1165-1172.
-
(2010)
Lancet
, vol.375
, pp. 1165-1172
-
-
Todo, Y.1
Kato, H.2
Kaneuchi, M.3
-
101
-
-
33750063659
-
Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients
-
Chan JK, Cheung MK, Huh WK et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 2006; 107: 1823-1830.
-
(2006)
Cancer
, vol.107
, pp. 1823-1830
-
-
Chan, J.K.1
Cheung, M.K.2
Huh, W.K.3
-
102
-
-
84860475076
-
Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis
-
Kim HS, Suh DH, Kim MK et al. Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis. Jpn J Clin Oncol 2012; 42: 405-412.
-
(2012)
Jpn J Clin Oncol
, vol.42
, pp. 405-412
-
-
Kim, H.S.1
Suh, D.H.2
Kim, M.K.3
-
103
-
-
84899654500
-
Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis
-
Vargas R, Rauh-Hain JA, Clemmer J et al. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol 2014; 133: 216-220.
-
(2014)
Gynecol Oncol
, vol.133
, pp. 216-220
-
-
Vargas, R.1
Rauh-Hain, J.A.2
Clemmer, J.3
-
104
-
-
84885173275
-
Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)?
-
Takano M, Ochi H, Takei Y et al. Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Br J Cancer 2013; 109: 1760-1765.
-
(2013)
Br J Cancer
, vol.109
, pp. 1760-1765
-
-
Takano, M.1
Ochi, H.2
Takei, Y.3
-
105
-
-
78049335265
-
Evaluation of parametrial spread in endometrial carcinoma
-
Watanabe Y, Satou T, Nakai H et al. Evaluation of parametrial spread in endometrial carcinoma. Obstet Gynecol 2010; 116: 1027-1034.
-
(2010)
Obstet Gynecol
, vol.116
, pp. 1027-1034
-
-
Watanabe, Y.1
Satou, T.2
Nakai, H.3
-
106
-
-
40749152740
-
Classification of radical hysterectomy
-
Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol 2008; 9: 297-303.
-
(2008)
Lancet Oncol
, vol.9
, pp. 297-303
-
-
Querleu, D.1
Morrow, C.P.2
-
107
-
-
80051550748
-
Surgical cytoreduction in stage IV endometrioid endometrial carcinoma
-
Shih KK, Yun E, Gardner GJ et al. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecol Oncol 2011; 122: 608-611.
-
(2011)
Gynecol Oncol
, vol.122
, pp. 608-611
-
-
Shih, K.K.1
Yun, E.2
Gardner, G.J.3
-
108
-
-
79956078774
-
The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study
-
Vandenput I, Trovik J, Vergote I et al. The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study. Int J Gynecol Cancer 2011; 21: 332-336.
-
(2011)
Int J Gynecol Cancer
, vol.21
, pp. 332-336
-
-
Vandenput, I.1
Trovik, J.2
Vergote, I.3
-
109
-
-
84925855902
-
Clinical outcomes of uterine carcinosarcoma: results of 94 patients
-
Gokce ZK, Turan T, Karalok A et al. Clinical outcomes of uterine carcinosarcoma: results of 94 patients. Int J Gynecol Cancer 2015; 25: 279-287.
-
(2015)
Int J Gynecol Cancer
, vol.25
, pp. 279-287
-
-
Gokce, Z.K.1
Turan, T.2
Karalok, A.3
-
111
-
-
13844256730
-
Lymphvascular space involvement: an independent prognostic factor in endometrial cancer
-
Briët JM, Hollema H, Reesink N et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol 2005; 96: 799-804.
-
(2005)
Gynecol Oncol
, vol.96
, pp. 799-804
-
-
Briët, J.M.1
Hollema, H.2
Reesink, N.3
-
112
-
-
0036921816
-
Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?
-
Cohn DE, Horowitz NS, Mutch DG et al. Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer? Gynecol Oncol 2002; 87: 243-246.
-
(2002)
Gynecol Oncol
, vol.87
, pp. 243-246
-
-
Cohn, D.E.1
Horowitz, N.S.2
Mutch, D.G.3
-
113
-
-
67650069978
-
Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer
-
Gadducci A, Cavazzana A, Cosio S et al. Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. Anticancer Res 2009; 29: 1715-1720.
-
(2009)
Anticancer Res
, vol.29
, pp. 1715-1720
-
-
Gadducci, A.1
Cavazzana, A.2
Cosio, S.3
-
114
-
-
34248566806
-
Lymphvascular space involvement compromises the survival of patients with stage I endometrial cancer: results of a multicenter study
-
Gemer O, Arie AB, Levy T et al. Lymphvascular space involvement compromises the survival of patients with stage I endometrial cancer: results of a multicenter study. Eur J Surg Oncol 2007; 33: 644-647.
-
(2007)
Eur J Surg Oncol
, vol.33
, pp. 644-647
-
-
Gemer, O.1
Arie, A.B.2
Levy, T.3
-
115
-
-
83055184368
-
Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer
-
Guntupalli SR, Zighelboim I, Kizer NT et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol 2012; 124: 31-35.
-
(2012)
Gynecol Oncol
, vol.124
, pp. 31-35
-
-
Guntupalli, S.R.1
Zighelboim, I.2
Kizer, N.T.3
-
116
-
-
58149186453
-
Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis
-
Blake P, Swart AM, Orton J et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009; 373: 137-146.
-
(2009)
Lancet
, vol.373
, pp. 137-146
-
-
Blake, P.1
Swart, A.M.2
Orton, J.3
-
117
-
-
18144432776
-
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma
-
Creutzberg CL, van Putten WL, Koper PC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000; 355: 1404-1411.
-
(2000)
Lancet
, vol.355
, pp. 1404-1411
-
-
Creutzberg, C.L.1
van Putten, W.L.2
Koper, P.C.3
-
118
-
-
1342321840
-
A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study
-
Keys HM, Roberts JA, Brunetto VL et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 744-751.
-
(2004)
Gynecol Oncol
, vol.92
, pp. 744-751
-
-
Keys, H.M.1
Roberts, J.A.2
Brunetto, V.L.3
-
119
-
-
84869016236
-
Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis
-
Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst 2012; 104: 1625-1634.
-
(2012)
J Natl Cancer Inst
, vol.104
, pp. 1625-1634
-
-
Kong, A.1
Johnson, N.2
Kitchener, H.C.3
Lawrie, T.A.4
-
120
-
-
0029738560
-
Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma
-
Soong R, Knowles S, Williams KE et al. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 1996; 74: 562-567.
-
(1996)
Br J Cancer
, vol.74
, pp. 562-567
-
-
Soong, R.1
Knowles, S.2
Williams, K.E.3
-
121
-
-
0032896335
-
Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study
-
Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 1999; 17: 1382-1390.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1382-1390
-
-
Salvesen, H.B.1
Iversen, O.E.2
Akslen, L.A.3
-
122
-
-
84901673573
-
Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer
-
AlHilli MM, Mariani A, Bakkum-Gamez JN et al. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Oncol 2014; 133: 485-493.
-
(2014)
Gynecol Oncol
, vol.133
, pp. 485-493
-
-
AlHilli, M.M.1
Mariani, A.2
Bakkum-Gamez, J.N.3
-
123
-
-
84881657484
-
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation
-
Zeimet AG, Reimer D, Huszar M et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 2013; 105: 1142-1150.
-
(2013)
J Natl Cancer Inst
, vol.105
, pp. 1142-1150
-
-
Zeimet, A.G.1
Reimer, D.2
Huszar, M.3
-
124
-
-
84907430202
-
L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results
-
Bosse T, Nout RA, Stelloo E et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. Eur J Cancer 2014; 50: 2602-2610.
-
(2014)
Eur J Cancer
, vol.50
, pp. 2602-2610
-
-
Bosse, T.1
Nout, R.A.2
Stelloo, E.3
-
125
-
-
69449098469
-
Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study
-
Sorbe B, Nordström B, Mäenpää J et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer 2009; 19: 873-878.
-
(2009)
Int J Gynecol Cancer
, vol.19
, pp. 873-878
-
-
Sorbe, B.1
Nordström, B.2
Mäenpää, J.3
-
126
-
-
77649130174
-
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
-
Nout RA, Smit VT, Putter H et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375: 816-823.
-
(2010)
Lancet
, vol.375
, pp. 816-823
-
-
Nout, R.A.1
Smit, V.T.2
Putter, H.3
-
127
-
-
84856376656
-
External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma-a prospective randomized study
-
Sorbe B, Horvath G, Andersson H et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma-a prospective randomized study. Int J Radiat Oncol Biol Phys 2012; 82: 1249-1255.
-
(2012)
Int J Radiat Oncol Biol Phys
, vol.82
, pp. 1249-1255
-
-
Sorbe, B.1
Horvath, G.2
Andersson, H.3
-
128
-
-
84938740095
-
Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer-a pooled analysis of PORTEC 1 and 2 trials
-
Bosse T, Peters EE, Creutzberg CL et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer-a pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 2015; 51: 1742-1750.
-
(2015)
Eur J Cancer
, vol.51
, pp. 1742-1750
-
-
Bosse, T.1
Peters, E.E.2
Creutzberg, C.L.3
-
129
-
-
84901633332
-
A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion
-
Bendifallah S, Canlorbe G, Raimond E et al. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion. Br J Cancer 2014; 110: 2640-2646.
-
(2014)
Br J Cancer
, vol.110
, pp. 2640-2646
-
-
Bendifallah, S.1
Canlorbe, G.2
Raimond, E.3
-
130
-
-
0344626922
-
Survival after relapse in patients with endometrial cancer: results from a randomized trial
-
Creutzberg CL, van Putten WL, Koper PC et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 2003; 89: 201-209.
-
(2003)
Gynecol Oncol
, vol.89
, pp. 201-209
-
-
Creutzberg, C.L.1
van Putten, W.L.2
Koper, P.C.3
-
131
-
-
84923088717
-
A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/ carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gynecologic Oncology Group trial
-
(abstract LBA 431)
-
McMeekin DS, Filiaci VL, Aghajanian C et al. A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/ carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gynecologic Oncology Group trial. Gynecol Oncol 2014; 134: 438 (abstract LBA 431).
-
(2014)
Gynecol Oncol
, vol.134
, pp. 438
-
-
McMeekin, D.S.1
Filiaci, V.L.2
Aghajanian, C.3
-
132
-
-
33845229580
-
Carcinoma of the corpus uter. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer
-
Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uter. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95(Suppl 1): S105-S143.
-
(2006)
Int J Gynaecol Obstet
, vol.95
, pp. S105-S143
-
-
Creasman, W.T.1
Odicino, F.2
Maisonneuve, P.3
-
133
-
-
0024997768
-
Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium
-
Greven KM, Randall M, Fanning J et al. Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 1990; 19: 529-534.
-
(1990)
Int J Radiat Oncol Biol Phys
, vol.19
, pp. 529-534
-
-
Greven, K.M.1
Randall, M.2
Fanning, J.3
-
134
-
-
0037404778
-
Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy
-
Straughn JM, Huh WK, Orr JW, Jr et al. Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy. Gynecol Oncol 2003; 89: 295-300.
-
(2003)
Gynecol Oncol
, vol.89
, pp. 295-300
-
-
Straughn, J.M.1
Huh, W.K.2
Orr, J.W.3
-
135
-
-
2142640269
-
Outcome of highrisk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial
-
Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC et al. Outcome of highrisk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 2004; 22: 1234-1241.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1234-1241
-
-
Creutzberg, C.L.1
van Putten, W.L.2
Wárlám-Rodenhuis, C.C.3
-
136
-
-
84936082191
-
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma
-
Sagae S, Susumu N, Viswanathan AN et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma. Int J Gynecol Cancer 2014; 24(9 Suppl 3): S83-S89.
-
(2014)
Int J Gynecol Cancer
, vol.24
, pp. S83-S89
-
-
Sagae, S.1
Susumu, N.2
Viswanathan, A.N.3
-
137
-
-
0025021388
-
Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study
-
Morrow CP, Bundy BN, Homesley HD et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol 1990; 36: 166-171.
-
(1990)
Gynecol Oncol
, vol.36
, pp. 166-171
-
-
Morrow, C.P.1
Bundy, B.N.2
Homesley, H.D.3
-
138
-
-
37349026899
-
Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study
-
Susumu N, Sagae S, Udagawa Y et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008; 108: 226-233.
-
(2008)
Gynecol Oncol
, vol.108
, pp. 226-233
-
-
Susumu, N.1
Sagae, S.2
Udagawa, Y.3
-
139
-
-
33746911931
-
Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial
-
Maggi R, Lissoni A, Spina F et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 2006; 95: 266-271.
-
(2006)
Br J Cancer
, vol.95
, pp. 266-271
-
-
Maggi, R.1
Lissoni, A.2
Spina, F.3
-
140
-
-
77955918294
-
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies
-
Hogberg T, Signorelli M, de Oliveira CF et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer 2010; 46: 2422-2431.
-
(2010)
Eur J Cancer
, vol.46
, pp. 2422-2431
-
-
Hogberg, T.1
Signorelli, M.2
de Oliveira, C.F.3
-
141
-
-
33748549388
-
Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer
-
Greven K, Winter K, Underhill K et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006; 103: 155-159.
-
(2006)
Gynecol Oncol
, vol.103
, pp. 155-159
-
-
Greven, K.1
Winter, K.2
Underhill, K.3
-
142
-
-
80052511021
-
Does the revised International Federation of Gynecology and Obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes?
-
Cooke EW, Pappas L, Gaffney DK. Does the revised International Federation of Gynecology and Obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes? Cancer 2011; 117: 4231-4237.
-
(2011)
Cancer
, vol.117
, pp. 4231-4237
-
-
Cooke, E.W.1
Pappas, L.2
Gaffney, D.K.3
-
143
-
-
84861485091
-
Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies? Revised staging, endometrial cancer, histology
-
Page BR, Pappas L, Cooke EW, Gaffney DK. Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies? Revised staging, endometrial cancer, histology. Int J Gynecol Cancer 2012; 22: 593-598.
-
(2012)
Int J Gynecol Cancer
, vol.22
, pp. 593-598
-
-
Page, B.R.1
Pappas, L.2
Cooke, E.W.3
Gaffney, D.K.4
-
144
-
-
64049094855
-
Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium
-
Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105: 103-104.
-
(2009)
Int J Gynaecol Obstet
, vol.105
, pp. 103-104
-
-
Pecorelli, S.1
-
145
-
-
0026060964
-
Relationship between surgicalpathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study
-
Morrow CP, Bundy BN, Kurman RJ et al. Relationship between surgicalpathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40: 55-65.
-
(1991)
Gynecol Oncol
, vol.40
, pp. 55-65
-
-
Morrow, C.P.1
Bundy, B.N.2
Kurman, R.J.3
-
146
-
-
62549128168
-
Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation
-
Wright JD, Fiorelli J, Kansler AL et al. Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. Am J Obstet Gynecol 2009; 200: 419.e1-419.e7.
-
(2009)
Am J Obstet Gynecol
, vol.200
, pp. 419.e1-419.e7
-
-
Wright, J.D.1
Fiorelli, J.2
Kansler, A.L.3
-
147
-
-
84898812959
-
The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline
-
Klopp A, Smith BD, Alektiar K et al. The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2014; 4: 137-144.
-
(2014)
Pract Radiat Oncol
, vol.4
, pp. 137-144
-
-
Klopp, A.1
Smith, B.D.2
Alektiar, K.3
-
148
-
-
37049029629
-
Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis
-
Rossi PJ, Jani AB, Horowitz IR, Johnstone PA. Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis. Int J Radiat Oncol Biol Phys 2008; 70: 134-138.
-
(2008)
Int J Radiat Oncol Biol Phys
, vol.70
, pp. 134-138
-
-
Rossi, P.J.1
Jani, A.B.2
Horowitz, I.R.3
Johnstone, P.A.4
-
149
-
-
0025334384
-
Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma
-
Randall ME, Wilder J, Greven K, Raben M. Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma. Int J Radiat Oncol Biol Phys 1990; 19: 49-54.
-
(1990)
Int J Radiat Oncol Biol Phys
, vol.19
, pp. 49-54
-
-
Randall, M.E.1
Wilder, J.2
Greven, K.3
Raben, M.4
-
150
-
-
13844301241
-
Preliminary analysis of RTOG 9708: adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer
-
Greven K, Winter K, Underhill K et al. Preliminary analysis of RTOG 9708: adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys 2004; 59: 168-173.
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.59
, pp. 168-173
-
-
Greven, K.1
Winter, K.2
Underhill, K.3
-
151
-
-
79957840766
-
Postoperative radiotherapy in stage I/II endometrial cancer: retrospective analysis of 883 patients treated at the University of Florence
-
Scotti V, Borghesi S, Meattini I et al. Postoperative radiotherapy in stage I/II endometrial cancer: retrospective analysis of 883 patients treated at the University of Florence. Int J Gynecol Cancer 2010; 20: 1540-1548.
-
(2010)
Int J Gynecol Cancer
, vol.20
, pp. 1540-1548
-
-
Scotti, V.1
Borghesi, S.2
Meattini, I.3
-
152
-
-
51749103754
-
Multicenter cohort study on treatment results and risk factors in stage II endometrial carcinoma
-
Jobsen JJ, Lybeert ML, van der Steen-Banasik EM et al. Multicenter cohort study on treatment results and risk factors in stage II endometrial carcinoma. Int J Gynecol Cancer 2008; 18: 1071-1078.
-
(2008)
Int J Gynecol Cancer
, vol.18
, pp. 1071-1078
-
-
Jobsen, J.J.1
Lybeert, M.L.2
van der Steen-Banasik, E.M.3
-
153
-
-
77956628579
-
Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma?
-
Crosby MA, Tward JD, Szabo A et al. Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma? Am J Clin Oncol 2010; 33: 364-369.
-
(2010)
Am J Clin Oncol
, vol.33
, pp. 364-369
-
-
Crosby, M.A.1
Tward, J.D.2
Szabo, A.3
-
154
-
-
84871918512
-
A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer
-
Secord AA, Geller MA, Broadwater G et al. A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol 2013; 128: 65-70.
-
(2013)
Gynecol Oncol
, vol.128
, pp. 65-70
-
-
Secord, A.A.1
Geller, M.A.2
Broadwater, G.3
-
155
-
-
69149098489
-
Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation
-
Klopp AH, Jhingran A, Ramondetta L et al. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol 2009; 115: 6-11.
-
(2009)
Gynecol Oncol
, vol.115
, pp. 6-11
-
-
Klopp, A.H.1
Jhingran, A.2
Ramondetta, L.3
-
156
-
-
33644836069
-
Randomized phase III trial of wholeabdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study
-
Randall ME, Filiaci VL, Muss H et al. Randomized phase III trial of wholeabdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006; 24: 36-44.
-
(2006)
J Clin Oncol
, vol.24
, pp. 36-44
-
-
Randall, M.E.1
Filiaci, V.L.2
Muss, H.3
-
157
-
-
84865692661
-
Combined chemotherapy and radiation improves survival for node-positive endometrial cancer
-
Lee LJ, Viswanathan AN. Combined chemotherapy and radiation improves survival for node-positive endometrial cancer. Gynecol Oncol 2012; 127: 32-37.
-
(2012)
Gynecol Oncol
, vol.127
, pp. 32-37
-
-
Lee, L.J.1
Viswanathan, A.N.2
-
158
-
-
0035425310
-
Significant pelvic recurrence in highrisk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy
-
Mundt AJ, McBride R, Rotmensch J et al. Significant pelvic recurrence in highrisk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50: 1145-1153.
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.50
, pp. 1145-1153
-
-
Mundt, A.J.1
McBride, R.2
Rotmensch, J.3
-
159
-
-
81155148254
-
The importance of chemotherapy and radiation in uterine papillary serous carcinoma
-
Viswanathan AN, Macklin EA, Berkowitz R, Matulonis U. The importance of chemotherapy and radiation in uterine papillary serous carcinoma. Gynecol Oncol 2011; 123: 542-547.
-
(2011)
Gynecol Oncol
, vol.123
, pp. 542-547
-
-
Viswanathan, A.N.1
Macklin, E.A.2
Berkowitz, R.3
Matulonis, U.4
-
160
-
-
84936108299
-
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix
-
Hasegawa K, Nagao S, Yasuda M et al. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Int J Gynecol Cancer 2014; 24(9 Suppl 3): S90-S95.
-
(2014)
Int J Gynecol Cancer
, vol.24
, pp. S90-S95
-
-
Hasegawa, K.1
Nagao, S.2
Yasuda, M.3
-
161
-
-
84871394939
-
The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer
-
Barney BM, Petersen IA, Mariani A et al. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. Int J Radiat Oncol Biol Phys 2013; 85: 109-115.
-
(2013)
Int J Radiat Oncol Biol Phys
, vol.85
, pp. 109-115
-
-
Barney, B.M.1
Petersen, I.A.2
Mariani, A.3
-
162
-
-
84923136396
-
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma
-
Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. Int J Gynecol Cancer 2014; 24(9 Suppl 3): S55-S60.
-
(2014)
Int J Gynecol Cancer
, vol.24
, pp. S55-S60
-
-
Berton-Rigaud, D.1
Devouassoux-Shisheboran, M.2
Ledermann, J.A.3
-
163
-
-
27144505774
-
The rationale for comprehensive surgical staging in endometrial carcinosarcoma
-
author reply 522-523
-
Amant F. The rationale for comprehensive surgical staging in endometrial carcinosarcoma. Gynecol Oncol 2005; 99: 521-522; author reply 522-523.
-
(2005)
Gynecol Oncol
, vol.99
, pp. 521-522
-
-
Amant, F.1
-
164
-
-
41849100978
-
Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)
-
Reed NS, Mangioni C, Malmstrom H et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44: 808-818.
-
(2008)
Eur J Cancer
, vol.44
, pp. 808-818
-
-
Reed, N.S.1
Mangioni, C.2
Malmstrom, H.3
-
165
-
-
54849407769
-
The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma
-
Wright JD, Seshan VE, Shah M et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol 2008; 199: 536.e1-536.e8.
-
(2008)
Am J Obstet Gynecol
, vol.199
, pp. 536.e1-536.e8
-
-
Wright, J.D.1
Seshan, V.E.2
Shah, M.3
-
166
-
-
49149090815
-
The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma
-
Clayton Smith D, Kenneth Macdonald O, Gaffney DK. The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. Radiother Oncol 2008; 88: 227-232.
-
(2008)
Radiother Oncol
, vol.88
, pp. 227-232
-
-
Clayton Smith, D.1
Kenneth Macdonald, O.2
Gaffney, D.K.3
-
167
-
-
52049118515
-
Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis
-
Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 2008; 111: 82-88.
-
(2008)
Gynecol Oncol
, vol.111
, pp. 82-88
-
-
Nemani, D.1
Mitra, N.2
Guo, M.3
Lin, L.4
-
168
-
-
35348917431
-
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus
-
Wolfson AH, Brady MF, Rocereto T et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007; 107: 177-185.
-
(2007)
Gynecol Oncol
, vol.107
, pp. 177-185
-
-
Wolfson, A.H.1
Brady, M.F.2
Rocereto, T.3
-
169
-
-
77953285328
-
Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis
-
Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 2010; 118: 14-18.
-
(2010)
Gynecol Oncol
, vol.118
, pp. 14-18
-
-
Barlin, J.N.1
Puri, I.2
Bristow, R.E.3
-
170
-
-
10044243565
-
Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium
-
Creasman WT, Kohler MF, Odicino F et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 2004; 95: 593-596.
-
(2004)
Gynecol Oncol
, vol.95
, pp. 593-596
-
-
Creasman, W.T.1
Kohler, M.F.2
Odicino, F.3
-
171
-
-
0038164996
-
Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy
-
Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys 2003; 56: 1366-1372.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.56
, pp. 1366-1372
-
-
Jhingran, A.1
Burke, T.W.2
Eifel, P.J.3
-
172
-
-
84922598070
-
Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification
-
Vargo JA, Kim H, Houser CJ et al. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification. Radiother Oncol 2014; 113: 126-131.
-
(2014)
Radiother Oncol
, vol.113
, pp. 126-131
-
-
Vargo, J.A.1
Kim, H.2
Houser, C.J.3
-
173
-
-
83055184395
-
Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma
-
Podzielinski I, Randall ME, Breheny PJ et al. Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma. Gynecol Oncol 2012; 124: 36-41.
-
(2012)
Gynecol Oncol
, vol.124
, pp. 36-41
-
-
Podzielinski, I.1
Randall, M.E.2
Breheny, P.J.3
-
174
-
-
0029867523
-
Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium
-
Fishman DA, Roberts KB, Chambers JT et al. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol 1996; 61: 189-196.
-
(1996)
Gynecol Oncol
, vol.61
, pp. 189-196
-
-
Fishman, D.A.1
Roberts, K.B.2
Chambers, J.T.3
-
175
-
-
84908280258
-
Image-based three-dimensional conformal brachytherapy for medically inoperable endometrial carcinoma
-
Gill BS, Kim H, Houser C et al. Image-based three-dimensional conformal brachytherapy for medically inoperable endometrial carcinoma. Brachytherapy 2014; 13: 542-547.
-
(2014)
Brachytherapy
, vol.13
, pp. 542-547
-
-
Gill, B.S.1
Kim, H.2
Houser, C.3
-
176
-
-
0033003177
-
Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group
-
Thigpen JT, Brady MF, Alvarez RD et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17: 1736-1744.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1736-1744
-
-
Thigpen, J.T.1
Brady, M.F.2
Alvarez, R.D.3
-
177
-
-
34548700355
-
Hormone therapy in advanced and recurrent endometrial cancer: a systematic review
-
Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007; 17: 964-978.
-
(2007)
Int J Gynecol Cancer
, vol.17
, pp. 964-978
-
-
Decruze, S.B.1
Green, J.A.2
-
178
-
-
84922481485
-
Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions
-
Tangen IL, Werner HM, Berg A et al. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. Eur J Cancer 2014; 50: 3003-3010.
-
(2014)
Eur J Cancer
, vol.50
, pp. 3003-3010
-
-
Tangen, I.L.1
Werner, H.M.2
Berg, A.3
-
179
-
-
0030032844
-
High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study
-
Lentz SS, Brady MF, Major FJ et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1996; 14: 357-361.
-
(1996)
J Clin Oncol
, vol.14
, pp. 357-361
-
-
Lentz, S.S.1
Brady, M.F.2
Major, F.J.3
-
180
-
-
0035863402
-
Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study
-
Thigpen T, Brady MF, Homesley HD et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001; 19: 364-367.
-
(2001)
J Clin Oncol
, vol.19
, pp. 364-367
-
-
Thigpen, T.1
Brady, M.F.2
Homesley, H.D.3
-
181
-
-
20844434805
-
The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers -a study of the National Cancer Institute of Canada Clinical Trials Group
-
Ma BB, Oza A, Eisenhauer E et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers -a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 2004; 14: 650-658.
-
(2004)
Int J Gynecol Cancer
, vol.14
, pp. 650-658
-
-
Ma, B.B.1
Oza, A.2
Eisenhauer, E.3
-
182
-
-
0033838806
-
A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study
-
Rose PG, Brunetto VL, VanLe L et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000; 78: 212-216.
-
(2000)
Gynecol Oncol
, vol.78
, pp. 212-216
-
-
Rose, P.G.1
Brunetto, V.L.2
VanLe, L.3
-
183
-
-
0742324890
-
Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study
-
Whitney CW, Brunetto VL, Zaino RJ et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 4-9.
-
(2004)
Gynecol Oncol
, vol.92
, pp. 4-9
-
-
Whitney, C.W.1
Brunetto, V.L.2
Zaino, R.J.3
-
184
-
-
0742307280
-
Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study
-
Fiorica JV, Brunetto VL, Hanjani P et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 10-14.
-
(2004)
Gynecol Oncol
, vol.92
, pp. 10-14
-
-
Fiorica, J.V.1
Brunetto, V.L.2
Hanjani, P.3
-
185
-
-
0037352608
-
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
-
van Wijk FH, Aapro MS, Bolis G et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003; 14: 441-448.
-
(2003)
Ann Oncol
, vol.14
, pp. 441-448
-
-
van Wijk, F.H.1
Aapro, M.S.2
Bolis, G.3
-
186
-
-
5444224343
-
Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study
-
Thigpen JT, Brady MF, Homesley HD et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004; 22: 3902-3908.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3902-3908
-
-
Thigpen, J.T.1
Brady, M.F.2
Homesley, H.D.3
-
187
-
-
2942657617
-
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study
-
Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22: 2159-2166.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2159-2166
-
-
Fleming, G.F.1
Brunetto, V.L.2
Cella, D.3
-
188
-
-
84870532408
-
Late-Breaking Abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study
-
Miller D, Filiaci V, Fleming G et al. Late-Breaking Abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012; 125: 771.
-
(2012)
Gynecol Oncol
, vol.125
, pp. 771
-
-
Miller, D.1
Filiaci, V.2
Fleming, G.3
-
189
-
-
84880434475
-
Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/ carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009
-
Makker V, Hensley ML, Zhou Q et al. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/ carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009. Int J Gynecol Cancer 2013; 23: 929-934.
-
(2013)
Int J Gynecol Cancer
, vol.23
, pp. 929-934
-
-
Makker, V.1
Hensley, M.L.2
Zhou, Q.3
-
190
-
-
84863686900
-
Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial Sloan-Kettering Cancer Center experience
-
Grisham RN, Adaniel C, Hyman DM et al. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial Sloan-Kettering Cancer Center experience. Int J Gynecol Cancer 2012; 22: 807-811.
-
(2012)
Int J Gynecol Cancer
, vol.22
, pp. 807-811
-
-
Grisham, R.N.1
Adaniel, C.2
Hyman, D.M.3
-
191
-
-
84888285940
-
Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/ Intergroup study
-
Nagao S, Nishio S, Michimae H et al. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/ Intergroup study. Gynecol Oncol 2013; 131: 567-573.
-
(2013)
Gynecol Oncol
, vol.131
, pp. 567-573
-
-
Nagao, S.1
Nishio, S.2
Michimae, H.3
-
192
-
-
78649559263
-
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? A Gynecologic Oncology Group ancillary data analysis
-
Moore KN, Tian C, McMeekin DS et al. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? A Gynecologic Oncology Group ancillary data analysis. Cancer 2010; 116: 5407-5414.
-
(2010)
Cancer
, vol.116
, pp. 5407-5414
-
-
Moore, K.N.1
Tian, C.2
McMeekin, D.S.3
-
193
-
-
84871121234
-
Molecular pathology of endometrial carcinoma
-
Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology 2013; 62: 111-123.
-
(2013)
Histopathology
, vol.62
, pp. 111-123
-
-
Matias-Guiu, X.1
Prat, J.2
-
194
-
-
63849308483
-
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation
-
Salvesen HB, Carter SL, Mannelqvist M et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 2009; 106: 4834-4839.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 4834-4839
-
-
Salvesen, H.B.1
Carter, S.L.2
Mannelqvist, M.3
-
195
-
-
84886394046
-
New strategies in endometrial cancer: targeting the PI3K/ mTOR pathway-the devil is in the details
-
Myers AP. New strategies in endometrial cancer: targeting the PI3K/ mTOR pathway-the devil is in the details. Clin Cancer Res 2013; 19: 5264-5274.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 5264-5274
-
-
Myers, A.P.1
-
196
-
-
84873059633
-
Endometrial carcinoma: molecular alterations involved in tumor development and progression
-
Yeramian A, Moreno-Bueno G, Dolcet X et al. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene 2013; 32: 403-413.
-
(2013)
Oncogene
, vol.32
, pp. 403-413
-
-
Yeramian, A.1
Moreno-Bueno, G.2
Dolcet, X.3
-
197
-
-
47249122523
-
Drug-sensitive FGFR2 mutations in endometrial carcinoma
-
Dutt A, Salvesen HB, Chen TH et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008; 105: 8713-8717.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 8713-8717
-
-
Dutt, A.1
Salvesen, H.B.2
Chen, T.H.3
-
198
-
-
37549006796
-
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer
-
Kamat AA, Merritt WM, Coffey D et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007; 13: 7487-7495.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 7487-7495
-
-
Kamat, A.A.1
Merritt, W.M.2
Coffey, D.3
-
199
-
-
84864330983
-
Markers for individualised therapy in endometrial carcinoma
-
Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 2012; 13: e353-e361.
-
(2012)
Lancet Oncol
, vol.13
, pp. e353-e361
-
-
Salvesen, H.B.1
Haldorsen, I.S.2
Trovik, J.3
-
201
-
-
79957949444
-
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
-
Aghajanian C, Sill MW, Darcy KM et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011; 29: 2259-2265.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2259-2265
-
-
Aghajanian, C.1
Sill, M.W.2
Darcy, K.M.3
-
202
-
-
84875435116
-
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
-
Colombo N, McMeekin DS, Schwartz PE et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer 2013; 108: 1021-1026.
-
(2013)
Br J Cancer
, vol.108
, pp. 1021-1026
-
-
Colombo, N.1
McMeekin, D.S.2
Schwartz, P.E.3
-
203
-
-
84913606847
-
Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer
-
Tsoref D, Welch S, Lau S et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol 2014; 135: 184-189.
-
(2014)
Gynecol Oncol
, vol.135
, pp. 184-189
-
-
Tsoref, D.1
Welch, S.2
Lau, S.3
-
204
-
-
84961812656
-
A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG86P
-
abstract 5500
-
Aghajanian C, Filiaci VL, Dizon DS et al. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG86P. J Clin Oncol 2015; 33(Suppl): abstract 5500.
-
(2015)
J Clin Oncol
, vol.33
-
-
Aghajanian, C.1
Filiaci, V.L.2
Dizon, D.S.3
-
205
-
-
84954370544
-
Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CPB) in advanced (stage III-IV) or recurrent endometrial cancer: the MITO END-2 trial
-
abstract 5502
-
Lorusso D, Ferrandina G, Colombo N et al. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CPB) in advanced (stage III-IV) or recurrent endometrial cancer: the MITO END-2 trial. J Clin Oncol 2015; 33(Suppl): abstract 5502.
-
(2015)
J Clin Oncol
, vol.33
-
-
Lorusso, D.1
Ferrandina, G.2
Colombo, N.3
-
206
-
-
84904516125
-
Current status of molecular biomarkers in endometrial cancer
-
Werner HM, Salvesen HB. Current status of molecular biomarkers in endometrial cancer. Curr Oncol Rep 2014; 16: 403.
-
(2014)
Curr Oncol Rep
, vol.16
, pp. 403
-
-
Werner, H.M.1
Salvesen, H.B.2
-
207
-
-
84865464494
-
Molecular targets and targeted therapeutics in endometrial cancer
-
Weigelt B, Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol 2012; 24: 554-563.
-
(2012)
Curr Opin Oncol
, vol.24
, pp. 554-563
-
-
Weigelt, B.1
Banerjee, S.2
-
208
-
-
84953228307
-
Phase 2 study of second-line dovitinib (TKI258) in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or -nonmutated advanced and/or metastatic endometrial cancer
-
Konecny GE, Finkler N, Garcia AA et al. Phase 2 study of second-line dovitinib (TKI258) in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or -nonmutated advanced and/or metastatic endometrial cancer. Ann Oncol 2014; 25(Suppl 4): LBA27.
-
(2014)
Ann Oncol
, vol.25
, pp. LBA27
-
-
Konecny, G.E.1
Finkler, N.2
Garcia, A.A.3
-
209
-
-
84893764401
-
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
-
Mackay HJ, Eisenhauer EA, Kamel-Reid S et al. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer 2014; 120: 603-610.
-
(2014)
Cancer
, vol.120
, pp. 603-610
-
-
Mackay, H.J.1
Eisenhauer, E.A.2
Kamel-Reid, S.3
-
211
-
-
84927154472
-
Basket trials and the evolution of clinical trial design in an era of genomic medicine
-
Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 2015; 33: 975-977.
-
(2015)
J Clin Oncol
, vol.33
, pp. 975-977
-
-
Redig, A.J.1
Jänne, P.A.2
|